Abacus FCF Advisors’s AstraZeneca AZN Stock Holding History

Abacus FCF Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,035	Closed	-$969K	–	127
2021 Q3	$969K	Buy	+8,035	New	+$935K	0.47%	107

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Abacus FCF Advisors's AZN Position: Q4 2021 in Review

Abacus FCF Advisors sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 8,035 shares — an estimated $969K sold.

Abacus FCF Advisors first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $969K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

Abacus FCF Advisors reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
Abacus FCF Advisors sold 8,035 AstraZeneca shares in Q4 2021, an estimated $969K.
Abacus FCF Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
Abacus FCF Advisors's AstraZeneca position peaked at $969K in Q3 2021.
949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Abacus FCF Advisors's 13F filing for Q4 2021, filed 10 Jan 2022.